One of the unique benefits of being a University of Michigan patient is access to the latest and most promising therapies for cancer. Patients play a vital role by participating in research studies -- also known as clinical trials.
A Phase I Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma
Principle Investigator: Theodore Welling, M.D.
A Phase 1 Study of LY2875358 in Patients with Advanced Cancer
Target: cMET (antibody)
Eligibility: Clear cell or papillary RCC, hepatocellular carcinoma with high cMET expression in tumor specimen, and uveal melanoma with liver mets.
Principle Investigator: Rashmi Chugh, M.D.
If you are interested in either of the above trials, please contact the Cancer AnswerLine at 1-800-865-1125.